Acknowledgments
This work was supported by the Wolfson Foundation and the NIHR Queen Square Dementia BRU. The Dementia Research Centre in an Alzheimer’s Research UK Coordinating Centre. Gratitude is due to the laboratory staff at the Sahlgrenska University Hospital for providing the CSF used in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Financial support: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5:48.10.1186/alzrt213Search in Google Scholar PubMed PubMed Central
2. U.S. Food and Drugs Administration. Guidance for industry bioanalytical method validation. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf. Accessed 27 October, 2014.Search in Google Scholar
3. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 2011;25:583–94.10.3233/JAD-2011-101911Search in Google Scholar PubMed
4. Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med 2013;51:2311–7.10.1515/cclm-2013-0293Search in Google Scholar PubMed
5. Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther 2014;6:5.10.1186/alzrt236Search in Google Scholar PubMed PubMed Central
6. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44.10.1038/nrneurol.2010.4Search in Google Scholar PubMed
7. ISO 5725-2, Accuracy (trueness and precision) of measurement methods and results – Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method. 1994.Search in Google Scholar
8. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2012. Available from: http://www.R-project.org/Search in Google Scholar
9. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team. nlme: linear and nonlinear mixed effects models. R package version 3.1-108. 2013.Search in Google Scholar
10. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33.10.1056/NEJMoa1304839Search in Google Scholar PubMed PubMed Central
©2015 by De Gruyter